Companies › Longeveron
1 active drug program in 1 registered trial: 1 Phase 2; Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lomecel-B Allogeneic human mesenchymal stem cells (MSCs) from bone marrow with signaling capacity | – | Phase 2 | Hypoplastic Left Heart Syndrome | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04925024 | Lomecel-B | Phase 2 | Hypoplastic Left Heart Syndrome | Other | Jun 2026 |
Cash of $10m on 2026-06-30; operating cash outflow about $20m a year; runway about 6 months at that burn, to Dec 2026
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Serum Life Science Europe Distribuidora Biolife SA de CV Circul'Egg Intervene Immune Biosolution
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.